Haoyun (Harry) An

Haoyun (Harry) An

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1997 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
HAHaoyun (Harry) An
Haoyun (Harry) An
BHBecky D. Haly
Becky D. Haly
AFAllister S. Fraser
Allister S. Fraser
CGCharles J. Guinosso
Charles J. Guinosso
PCP. Dan Cook
P. Dan Cook

9 December 2015 in Beilstein Journal of Organic Chemistry
Verified
Journal Article
Open access
PDF file
HRHang Ren
Hang Ren
HAHaoyun (Harry) An
Haoyun (Harry) An
PHPaul J. Hatala
Paul J. Hatala
WSWilliam C Stevens
William C Stevens
TCTao Jing Chao
Tao Jing Chao
BHBaicheng He
Baicheng He
A unified synthetic strategy accessing novel 3'-fluorinated purine nucleoside derivatives and their biological evaluation were achieved. Novel 3’-fluorinated analogues were constructed from a common 3’-deoxy-3’-fluororibofuranose intermediate. Employing Suzuki and Stille cross-coupling reactions, fifteen 3’-fluororibose purine nucleosides1–15and eight 3’-fluororibose 2-chloro/2-aminopurine nucleosides16–23with various substituents at position 6 of the purine ring were efficiently synthesized. Furthermore, 3’-fluorine analogs of natural products nebularine and 6-methylpurine riboside were constructed via our convergent synthetic strategy. Synthesized nucleosides were tested against HT116 (colon cancer) and 143B (osteosarcoma cancer) tumor cell lines. We have demonstrated 3’-fluorine purine nucleoside analogues display potent tumor cell growth inhibition activity at sub- or low micromolar concentration.

11 March 2019 in Molecules
Verified
Journal Article
Open access
PDF file
HRHang Ren
Hang Ren
HAHaoyun (Harry) An
Haoyun (Harry) An
TCTao Jing Chao
Tao Jing Chao
Glycosylation of 6-amino-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine and its iodo- and bromo- analogues with the protected ribofuranose and 2′-deoxyribofuranose under different conditions resulted in the synthesis of N9- and N8-glycosylated purine nucleosides. Five key intermediate nucleosides, having 6-methoxy, 7-iodo, and 2-bromo groups, were further derivatized to 23 final 8-aza-7-deazapurine nucleoside derivatives. The structures of N9- and N8-glycosylated products were assigned based on UV and NMR spectra. HMBC analysis of 2D NMR spectra and X-ray crystallographic studies of the representative compounds unambiguously verified the connection of ribose ring to N9- or N8-position of the purine ring. The anticancer activity of these new compounds was evaluated.


1 January 2018 in Chinese Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
HRHang Ren
Hang Ren
JTJingchao Tao
Jingchao Tao
HAHaoyun (Harry) An
Haoyun (Harry) An

31 March 2023
Verified
Other
Open access
WXWanhong Xu
Wanhong Xu
BXBiao Xi
Biao Xi
JWJieying Wu
Jieying Wu
HAHaoyun (Harry) An
Haoyun (Harry) An
JZJenny Zhu
Jenny Zhu
XXXiao Xu
Xiao Xu
Bis(4-fluorobenzyl)trisulfide (BFBTS) is a synthetic molecule derived from a bioactive natural product, dibenzyltrisulfide, found in a subtropical shrub, Petiveria allieacea. BFBTS has potent anticancer activities to a broad spectrum of tumor cell lines with IC50 values from high nanomolar to low micromolar and showed equal anticancer potency between tumor cell lines overexpressing multidrug-resistant gene, MDR1 (MCF7/adr line and KBv200 line), and their parental MCF7 line and KB lines. BFBTS inhibited microtubule polymerization dynamics in MCF7 cells, at a low nanomolar concentration of 54 nmol/L, while disrupting microtubule filaments in cells at low micromolar concentration of 1 μmol/L. Tumor cells treated with BFBTS were arrested at G2-M phase, conceivably resulting from BFBTS-mediated antimicrotubule activities. Mass spectrometry studies revealed that BFBTS bound and modified β-tubulin at residue Cys12, forming β-tubulin-SS-fluorobenzyl. The binding site differs from known antimicrotubule agents, suggesting that BFBTS functions as a novel antimicrotubule agent. BFBTS at a dose of 25 mg/kg inhibited tumor growth with relative tumor growth rates of 19.91%, 18.5%, and 23.42% in A549 lung cancer, Bcap-37 breast cancer, and SKOV3 ovarian cancer xenografts, respectively. Notably, BFBTS was more potent against MDR1-overexpressing MCF7/adr breast cancer xenografts with a relative tumor growth rate of 12.3% than paclitaxel with a rate of 43.0%. BFBTS displays a novel antimicrotubule agent with potentials for cancer therapeutics. [Mol Cancer Ther 2009;8(12):3318–30]